Lactulose Mip

Lactulose, the active ingredient in Lactulose Mip, is an osmotic laxative presented as an oral formulation for oral use. It is employed to relieve constipation and to manage hepatic encephalopathy in patients with liver disease.

GNH USA supplies Lactulose Mip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Lactulose is used in clinical practice to address conditions related to intestinal motility and ammonia accumulation.

- Constipation: softens stools and promotes regular bowel movements in patients with functional or opioid‑induced constipation. - Hepatic encephalopathy: lowers blood ammonia levels, helping to treat acute episodes in cirrhotic patients. - Prevention of hepatic encephalopathy recurrence: used as maintenance therapy to reduce the risk of future episodes.

Lactulose may cause a range of adverse reactions, most of which are related to its osmotic activity in the gastrointestinal tract.

Common Side Effects: - Abdominal bloating - Flatulence - Diarrhea - Nausea - Abdominal cramps - Increased thirst

Serious or Rare Side Effects: - Severe dehydration - Electrolyte imbalance (e.g., hypokalemia) - Allergic reactions such as rash or urticaria - Severe abdominal pain - Worsening of hepatic encephalopathy symptoms - Anaphylaxis (very rare)

When prescribing or dispensing Lactulose, several safety considerations should be observed.

- Assess renal function: impaired clearance may increase systemic exposure. - Monitor electrolytes: osmotic diarrhea can lead to electrolyte disturbances. - Use caution in diabetic patients: the product contains small amounts of sugar. - Avoid abrupt discontinuation: may result in rebound constipation. - Adjust dose in hepatic impairment: titrate to clinical response. - Store at room temperature: keep in the original container, protect from moisture.

Lactulose can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant use with strong stimulant laxatives: risk of severe diarrhea and electrolyte loss. - Antidiarrheal agents (e.g., loperamide): may diminish Lactulose's therapeutic effect. - Intravenous hyperosmolar solutions: additive osmotic load can exacerbate fluid shifts.

Moderate Interactions (Monitor Closely): - Antibiotics such as rifaximin: may alter gut flora and affect ammonia metabolism. - Oral hypoglycemic agents: sugar content may influence glucose control. - Diuretics: combined effect may increase risk of electrolyte imbalance.